We report here an improved radiosynthesis and purification of [F-18]EF5 by utilizing an electroformed nickel (Ni) target for [F-18]F-2 production, and Oasis (R) HLB cartridges for on-line solid phase extraction of [F-18]EF5
prior to HPLC purification.
Methods: [F-18]F-2 was produced by deuteron bombardment of neon plus F-2 in an Ni target, and bubbled through the radiolabelling precursor solution. Purification was achieved by extracting the contents of the crude reaction mixture onto Oasis HLB cartridges, and subsequently eluted onto a semi-preparative HPLC column for further separation. Purified [F-18]EF5 was evaluated in small animal PET studies using HCT116 tumor xenografts in nude mice.
Results: The electroformed Ni target enabled recovery of >75% of the radioactivity from the cyclotron https://www.selleckchem.com/products/brigatinib-ap26113.html target, resulting in 16.2 +/- 2.2 GBq (438 +/- 58 mCi) of [F-18]F-2 available for the synthesis. Use of Oasis cartridges yielded a less complex mixture for purification. On average, 1140 +/- 200 MBq (30.8 +/- 5.4 mCi) of [F-18]EF5 were find more collected at EOS. Small animal PET imaging studies showed specific retention of [F-18]EF5 in tumors, with tumor-to-muscle ratios of 2.7 +/- 0.3 at aboutl 60 min after
injection.
Conclusion: A simple procedure has been developed for the routine synthesis of [F-18]EF5 in amounts and purity required for clinical studies. This new method avoids the need for TFA evaporation and also enables facile automation of the synthesis using commercially available radiosynthesis modules. (c). 2012 Elsevier Inc. All rights reserved.”
“Objectives: We reviewed the use of pediatric mechanical circulatory support before and after transplantation to examinine current results and future strategies.
Methods: All patients listed for transplantation from January 2000 to December 2010 who required either extracorporeal membrane oxygenation (ECMO) or ventricular assist device (VAD) support before (“”intention to transplant”) or
after transplantation were included. Indications for mechanical assistance, age, weight, duration of support, complications while on support, causes of death, learn more and overall actuarial survival were recorded.
Results: Thirty-seven patients were received VADs; 32 (86.5%) survived to transplantation. Postoperative hemorrhagic or thrombotic complications affected all of those under 15 kg. One patient in the survivor cohort demonstrated focal neurologic findings. Three (8.1%) had panel reactive antibody levels of 10% or more while on device support; all received transplants. ECMO as an intention to bridge to transplantation was used in 28 patients; 7 died, 7 were weaned, and 14 were bridged to transplantation. Nineteen patients required ECMO after transplantation; 3 additional patients had percutaneous VAD support for late rejection. There was a significant (P = .